Volume 7 Supplement 1
Monitoring and evaluation of malaria in pregnancy – developing a rational basis for control
© Brabin et al; licensee BioMed Central Ltd. 2008
Published: 11 December 2008
Monitoring and evaluation of malaria control in pregnancy is essential for assessing the efficacy and effectiveness of health interventions aimed at reducing the major burden of this disease on women living in endemic areas. Yet there is no currently integrated strategic approach on how this should be achieved. Malaria control in pregnancy is formulated in relation to epidemiological patterns of exposure. Current emphasis is on intermittent preventive treatment (IPTp) during pregnancy with sulphadoxine-pyrimethamine in higher transmission areas, combined with insecticide treated bed nets (ITNs) and case management. Emphasis in lower transmission areas is primarily on case management. This paper discusses a rational basis for monitoring and evaluation based on: assessments of therapeutic and prophylactic drug efficacy; proportional reductions in parasite prevalence; seasonal effects; rapid assessment methodologies; birthweight and/or anaemia nomograms; case-coverage methods; maternal mortality indices; operational and programmatic indicators; and safety and pharmacovigilance of antimalarials in pregnancy. These approaches should be incorporated more effectively within National Programmes in order to facilitate surveillance and improve identification of high-risk women. Systems for utilizing routinely collected data should be strengthened, with greater attention to safety and pharmacovigilance with the advent of artemisinin combination therapies, and prospects of inadvertent exposures to artemisinins in the first trimester. Integrating monitoring activities within malaria control, reproductive health and adolescent-friendly services will be critical for implementation. Large-scale operational research is required to further evaluate the validity of currently proposed indicators, and in order to clarify the breadth and scale of implementation to be deployed.
Malaria in pregnancy is an immense public health problem with at least 50 million pregnant women living in malaria endemic areas . Under conditions of high transmission there is increased Plasmodium falciparum parasite prevalence in placental and peripheral blood, which is higher in first, compared to later, pregnancies. This epidemiological pattern for P. falciparum has been recognized for many years, with higher prevalence in early pregnancy which increases, if untreated, and then decreases as gestation progresses [2–4]. In stable high transmission areas, almost all primigravidae, if unprotected, are likely to be infected in early pregnancy and approximately half of these would remain infected by the time of delivery if untreated. In multigravidae, especially in higher parities, prevalence is significantly reduced due to the acquisition of parity-specific immunity . Maternal HIV infection is associated with increased P. falciparum prevalence and delays clearance of parasitaemia in multigravidae.
A changing situation
Summary of WHO recommended indicators for monitoring and evaluation of programmes to control malaria during pregnancy.
1. Percentage of antenatal clinic staff (pre-service, in-service or at supervisory visits) trained in control of malaria during pregnancy in the past 12 months (including IPT, counselling on ITN use and case management for pregnancy women).
2. Percentage of health facilities reporting stock-out of the recommended drug for IPT (currently sulphadoxine-pyrimethamine) in the past month.
3. Percentage of pregnant women attending antenatal care who receive IPT under direct observation (first dose, second dose, third dose).
4. Percentage of pregnant women who report having slept under an ITN the previous night.
5. Percentage of low birth-weight singleton live births (< 2500 g), by parity.
6. Percentage of screened pregnant women with severe anaemia (haemoglobin 7 g/dl) in third trimester 7, by gravidity.
To assess progress in the delivery of interventions for the control of malaria in pregnancy, and their effectiveness, a number of core indicators of process, outcome and impact have been identified in order to guide national programmes . In this paper, some new indicators, are reviewed as well as established assessment approaches, for monitoring and evaluation of malaria control in pregnancy and the rational basis for their implementation.
Antimalarial drug efficacy
The Global Malaria Programme of the World Health Organization (WHO) is developing a framework to monitor and evaluate the efficacy and effectiveness of SP-ITPp on pregnancy outcome in the context of SP resistance and in the absence of continued SP testing in children which previously has been used as a proxy for assessing resistance. The mechanism of action of SP-based IPTp is not yet well established, despite the widely advocated use of the strategy in high transmission settings. SP, a long half-life drug, is expected to be effective by both clearing malaria infections and through post-treatment prophylaxis. For monitoring SP efficacy for IPTp, both therapeutic and preventive efficacy of the medicine, therefore, needs to be assessed.
There is a well-established standard methodology for monitoring antimalarial therapeutic efficacy, which involves repeated assessment of clinical and parasitological responses to treatment during a fixed period of follow-up in order to detect any reappearance of symptoms/signs and/or parasites in the blood as an indication of reduced sensitivity to a particular drug. There is currently no standard protocol for monitoring preventive efficacy, an important component of IPT. Evidence suggests that re-infections of falciparum malaria occur progressively earlier as resistance intensifies, shortening the post-treatment prophylaxis period . Therefore, both the rate of re-infection and duration of time-to-reinfection could be useful indicators for measuring the preventive efficacy of IPTp. These measurements should be related to the desired outcomes of IPTp.
Assessing the therapeutic efficacy response to the IPTp first dose (IPTp × 1), can be achieved using the current standard WHO in vivo protocol , with the following modifications: (i) pregnant women with asymptomatic falciparum infections should be recruited as the study group, (ii) clearance of the parasitaemias at a first antenatal visit in the second trimester, should be monitored, (iii) a 42-day follow-up design should be used, with scheduled visits on days 0, 3, 7, 14, 21, 28 and 42 following administration of IPTp first treatment, (iv) the second IPTp dose would be given following completion of the 42-day follow up, unless rescue treatment was required. According to the WHO in vivo protocol , the duration of follow-up for therapeutic efficacy is 28 days, and, as the recommended interval between two IPTp doses is at least one month, a 28-day follow-up is practical and logical. The prophylactic effect of SP in infants has been shown to be about 4–5 weeks and one might expect this to be longer in pregnant women infected with parasites of the same level of sensitivity because of the presence of some immunity. For this reason, a 42-day follow-up should be included.
Recrudescence should be differentiated from re-infection through determination of msp1 and msp2 genotypes using PCR. SP resistance is associated with mutations in the dihydrofolate reductase (pfdhfr) and dihydropteroate synthase (pfdhps) genes. Characterization of these resistance molecular markers would provide additional information on SP resistance and should be assessed.
Post-treatment prophylaxis could be measured using the above approach assessing the occurrence of new falciparum infections and time to re-infection in uninfected pregnant women within 42 days following administration of IPTp. This could be measured either in previously untreated, aparasitaemic pregnant women, or in women who were parasitaemic and had cleared the parasites after the first SP dose. Either of these options would be suitable, but assessment should not include a combination of both. The proportional reduction in parasite prevalence between the time when IPTp × 1 is received until delivery is an assessment of both therapeutic efficacy and post-treatment prophylaxis. With more frequent IPTp doses this indicator provides an estimate of the total post-treatment prophylaxis effect. This would be a useful composite indicator of both drug resistance and prophylactic efficacy in women receiving IPTp.
What are the monitoring and evaluation implications of malaria seasonality?
Rapid assessment methodology
A methodology for this has been published based on cross-sectional prevalence assessments of maternal parasitaemia, maternal anaemia (Hb <11.0 g/dl for moderate anaemia and <7.0 g/dl for severe anaemia) and low birthweight (<2,500 gms), categorized by gravida class . These indicators significantly improve with use of SP-IPTp and/or ITNs [20, 21]. Sentinel surveys monitoring these parameters are important for baseline surveys as well as for evaluating subsequent interventions. A slightly higher haemoglobin cut-off, indicating moderately severe anaemia (Hb < 8.0 g/dl), has been frequently used in prevalence assessments and has the advantage that it may be more sensitive to malaria-related changes in haemoglobin concentration in pregnant women living under stable transmission conditions .
Birthweight and anaemia nomograms
Maternal anaemia has also been proposed as an indicator for monitoring malaria control in sub-Saharan Africa , based on the excess of risk of anaemia in primigravidae compared to multigravidae. This difference is usually observed at first antenatal clinic attendance in women living in malarious areas. An anaemia nomogram has been developed to assess changes in this excess risk with altered malaria exposure . This requires systematic evaluation in view of its combined utility for use in antenatal clinics as well as for monitoring malaria control in pregnancy. It provides a standardized assessment format for comparative evaluations. Sensitivity and specificity estimates are good using either moderate (Hb <11.0 g/dl), or severe anaemia (Hb <8.0 g/dl), for the cut-off values .
A key issue is the quality and frequency of assessment of antenatal haemoglobin in most countries in sub-Saharan Africa. This is becoming an increasingly important issue in view of the sustained, high prevalence of anaemia, often severe, in women living in malarious areas and which is not attributable to iron deficiency alone [22, 27]. Screening, recognition and appropriate management of pregnancy anaemia is a pivotal aspect of antenatal care and strategies of assessment should be more effectively linked to the monitoring of malaria control in pregnancy. The WHO currently recommends screening for anaemia in pregnancy .
Case coverage method
The screening method used for estimating vaccine efficacy has been applied recently as a surveillance tool for estimating drug effectiveness of SP-IPTp in reducing either low birthweight or anaemia prevalence during pregnancy . The case-coverage method requires birthweight, anaemia, or placental malaria data and knowledge of frequency of use of SP-IPTp during pregnancy. It also has potential utility for estimating ITN effectiveness, providing data on ITN coverage in pregnant women is available and the frequency with which women use ITNs.
This is an important complication of malaria in pregnancy and in lower transmission settings may result directly from severe malaria , or in higher transmission areas, indirectly, from severe anaemia . With improved malaria control, maternal mortality indicators should improve and show reduced seasonal variation. As mortality indicators are routinely collected in many regions, there is a need for surveillance methodologies linking them to malaria intervention strategies and which allow seasonal analyses. Large sample sizes are needed for these analyses and population-based demographic health surveillance databases would be suitable.
Operational and programmatic indicators
In order to improve access to antimalarial interventions targeting pregnant women, Reproductive Health Programmes are central to effective implementation. The high rate of antenatal attendance of at least two visits reported in sub-Saharan Africa is encouraging as an entry point for reaching pregnant women with antimalarial interventions. The gestational age of first visit and attendance of adolescents are two issues, which influence the effectiveness of programmes. This is because the burden of malaria in pregnancy is higher with late attendance as the intervention comes too late in pregnancy; also adolescents are the highest risk group due to both their young age and nulliparity. Adolescents living in malarious areas have poorer pregnancy outcomes compared to older women [31, 32], and identification and evaluation of indicators in this vulnerable group is an important aspect of malaria control. There is also evidence in adolescent girls of a partial reversal during puberty of age-dependent malaria immunity (G. Kalanda, personal communication).
Although collection of antenatal attendance indicators is important, high attendance does not necessarily translate into high IPTp coverage  and updated information on SP-IPTp and ITN coverage and use among pregnant women living in high malaria transmission areas is essential to ensure that women in remote areas are accessing antimalarial interventions. Distance indicators should also be considered. There is evidence from rural Tanzania that mean birthweight for dispensary deliveries is associated with distance from the main district hospital, with deliveries occurring at 25 km or greater distances at highest risk for low birthweight . ITPp was not implemented effectively in these rural districts and women further away from the main town may have received less health education regarding the consequences of malaria in pregnancy and had fewer opportunities for referral.
Strategies promoting SP-IPTp and ITN use for pregnant women are required. Indicators of health promotion activities through existing services should be assessed in areas of low coverage of interventions with a view to developing promotional activities targeted to pregnant women. There is evidence that these campaigns can lead to major increases in coverage , particularly as, even with knowledge of malaria in pregnancy, women also may express concerns that antimalarials have adverse effects on their baby and as a result can show reluctance to purchase these drugs . Linked to this is the need for indicators of staff training, as well as research on the use of teaching aids, including diagrams which can be used as examples to show malaria burden estimates as illustrated in Figures 3 to 6.
Monitoring safety of antimalarials
Monitoring the safety of antimalarial drugs during pregnancy is an essential part of public health programmes. WHO recommends the integration of pharmacovigilance in public health programmes to ensure their acceptance and effectiveness . Evidence on the safety of drugs implemented by national malaria control programmes has the potential to increase programme success by providing guidance on reducing the risks of adverse reactions thereby increasing overall public trust. Furthermore, comparing the risk-benefit profiles of different antimalarial drugs would allow evidence-based decisions to be taken on the most effective as well as safer and better tolerated interventions. Adverse drug reactions, particularly serious adverse events affecting pregnancy outcomes (such as pregnancy loss or congenital anomalies) or severe skin reactions, can have serious public health impact and spoil confidence in any national programme. This can also lead to poor adherence, which in turn can result in treatment failure and increase the risk of development of parasite resistance leading to reduced efficacy.
Most countries in sub-Saharan Africa have little infrastructure and few resources for routine pharmacovigilance and very few have a formal system for routine collection of data on possible drug-related adverse effects [36, 37]. The extrapolation of safety data derived from industrialised countries is limited by the type of drugs used in countries with established pharmacovigilance systems (i.e. with sparse experience of drugs for tropical diseases), the underlying differences in populations in terms of genetic make up, diet and health-seeking behaviour. Additionally, high levels of co-morbidities and concomitant medication use (such as for HIV, TB, malaria and other infections), as well as the use of traditional remedies in developing countries can increase the risk of drug interactions and adverse reactions. The concern is great for vulnerable groups like pregnant women. There is often limited information on the safety of drugs in this group as pregnant women are systematically excluded from pre-licensure clinical trials out of concern for not harming the mother or her unborn baby.
The process of establishing risk or safety of drugs used in pregnancy requires special considerations and involves the systematic recording of data on drug exposure and pregnancy outcomes. One of the most established approaches is the "Pregnancy Exposure Registry", a prospective, observational study monitoring outcomes of pregnancies exposed to specific drugs. This approach requires significant resources, but can be time-limited . Much attention has been given to the establishment of an international antimalarial exposure registry due the widespread implementation of artemisinin combination therapies (ACTs) as first-line therapies in Africa and the uncertainty of their safety in early pregnancy . There is a need to establish simple but effective pharmacovigilance systems to detect early signals of any major teratogenic effect associated with a prenatal exposure to antimalarial drugs. Such safety issues could have serious consequences for public health, and successful implementation of the recommended strategy for malaria in pregnancy requires reliable safety profiles for antimalarial drugs in use in order to inform policy makers, national malaria control programmes and health care providers. This will require close and effective collaboration between the different stakeholders (including policy makers, pharmacovigilance experts, the pharmaceutical industry and health care providers). Safety monitoring will assist in achieving the goals of national malaria control programmes and is thus an important indicator to be included in a monitoring and evaluation strategy.
Monitoring and evaluation indicators, tools and assessment methods: output indicators.
1. SP-IPTp coverage
Proportion of pregnant women with two SP-IPTp treatments in women delivering at health facilities or with home deliveries
80% of pregnant women receive IPTp in stable transmission areas
Health facility surveys and health promotion assessments
Missed opportunities; health promotion assessment; use of new promotion tools
2. ITN coverage
Proportion of pregnant and non-pregnant women with ITNs, properly deploying (adherence) and properly treated with insecticides
100% of pregnant women at risk from malaria are protected
Health facility and community surveys; health promotion assessments
Missed opportunities; promotion assessment; use of new promotion tools
Proportion of adolescents deploying ITNs
100% coverage. New indicator
Female adolescent friendly health services (AFHS)
Evaluation of AFHS incorporating malaria control activities
Proportion using ITNs prior to first pregnancy
100% coverage. New indicator
Periodic cross-sectional surveys
3. Proportion of pregnant women diagnosed and promptly treated with recommended drug
All malaria patients correctly diagnosed and treated
Hospital surveys and case fatality rates
Adherence to first-line therapy
4. Staff training
Proportion completing training programme
All ANC and malaria programme staff
Curriculum content and feedback; use of diagrams illustrating malaria burden
Monitoring and evaluation indicators, tools and assessment methods: impact indicators.
1. Birthweight and anaemia
Low birthweight and maternal anaemia prevalence (Hb <10 g/dl and <8 g/dl) by parity
Reduced prevalence of low birthweight and anaemia
Rapid assessment methodologies; annual hospital wet season surveys
Birthweight and anaemia nomograms; annual trends and changes with new interventions
Malaria prevalence at delivery
Health facility surveys
Use of rapid diagnostic tests
2. Maternal mortality
Declining maternal mortality rates
Demographic health surveys and hospital case fatality rates
Seasonal mortality patterns and severe anaemia and malaria mortality rates
Monitoring and evaluation indicators, tools and assessment methods: programmatic indicators.
1. Identification of high risk individuals
Proportion of adolescent ANC attendees
>80% of adolescents attending ANC
Health facility assessments
Strategies for delaying pregnancies
Proportion of primigravidae with late ANC attendance
< 10% attendees
Health facility assessment
Reasons for late attendance
Distance indicators of household residence from main health facility
Identification of high risk areas
Community SP-IPTp distribution
Antenatal HIV infection
Mother to child HIV transmission assessments
Implementation of HIV prevention strategies
2. Antimalarial drug efficacy estimates
Antimalarial therapeutic efficacy
Agreed surveillance interval (2–5 years)
Antimalarial in vivo sensitivity tests
Comparative drug evaluations
Proportional reduction in parasitaemia between first antenatal visit and delivery
Health facility prevalence estimate
Comparison with birthweight or anaemia outcomes
Proportion of women with placental infection who have received two SP-IPTp doses
Assessment in sentinel health facilities
Case-coverage methodology for determining SP-ITPp efficacy
Comparison of case-coverage efficacy estimates method with in vivo tests
Antimalarial post-treatment prophylaxis
Agreed surveillance interval (2–5 years)
Antimalarial prophylactic efficacy tests
Evaluation in aparasitaemic women on IPTp
3. Safety indicators
Inadvertent antimalarial drug exposure in first trimester
No exposures in asymptomatic women
Cross-sectional household/health facility surveys
Prevalence estimates and associated pregnancy outcomes
Assessment of safety indicators via national and international antimalarial exposure registry
Establishing functional registry
Standardized protocol under development by WHO
Demonstration sites; new methods for drug exposure, ascertainment, congenital anomaly detection
Whilst challenging, an effective partnership between the Ministries of Health and local research institutions is essential. The Ministry of Health could provide the necessary framework for routine health system data collection on the one hand (for output and outcome indicators), and research institutions and other partners providing the expertise for monitoring drug efficacy and programme effectiveness. Additional partners would be required to set up effective safety monitoring, such as policy makers and the pharmaceutical industry.
Tables 2, 3, 4 outline the tools available, and where and how each of the proposed indicators are collected, through health facilities, household surveys, sentinel surveillance or national monitoring. The frequency of collection of this information in part depends on the level of malaria exposure which women experience. This relates to their disease burden and levels of drug resistance, and also on the cost, level of complexity of the survey method, and whether the data would be collected through the health system or by separately conducted research studies. The translation of research findings into effective programmatic activities requires this on-going surveillance at these different levels. This should also ensure the equitable distribution of interventions to higher risk groups. Monitoring indicators should also be incorporated within relevant research studies in order to facilitate relating research study findings to concurrent programme evaluations.
Systematic monitoring should be co-ordinated at national and regional levels to facilitate summary analyses of basic indicators. Surveillance should encourage the formulation of appropriate databases, which could be updated with routinely collected pregnancy data. Data linkage would allow assessment of trends for seasonal indicators, allowing their utility to be assessed under changing epidemiological conditions. With increasing efforts towards the global eradication of malaria there is an urgent need for strengthening health management information systems for improved measurement and surveillance of control interventions in general, including special risk groups such as pregnant women and adolescents.
We are grateful to Luke Brabin and Gibby Koshy for preparation of the figures and to Dr Peter Olumese for his helpful comments.
This article has been published as part of Malaria Journal Volume 7 Supplement 1, 2008: Towards a research agenda for global malaria elimination. The full contents of the supplement are available online at http://www.malariajournal.com/supplements/7/S1
- WHO/AFRO: A strategic framework for malaria prevention and control during pregnancy in the African region. 2004, World Health Organization Regional Office for AfricaGoogle Scholar
- Brabin BJ: An analysis of malaria in pregnancy in Africa. Bull World Health Organ. 1983, 61: 1005-1016.PubMed CentralPubMedGoogle Scholar
- Gilles HM, Lawson JB, Sibelas M, Voller A, Allan N: Malaria, anaemia and pregnancy. Ann Trop Med Parasit. 1969, 63: 245-263.PubMedGoogle Scholar
- McGregor IA, Wilson ME, Billewicz WZ: Malaria infection of the placenta in The Gambia, West Africa; its incidence and relationship to stillbirth, birthweight and placental weight. Trans R Soc Trop Med Hyg. 1983, 77: 232-244. 10.1016/0035-9203(83)90081-0.View ArticlePubMedGoogle Scholar
- Fried M, Duffy PE: Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science. 1996, 272: 1502-1504. 10.1126/science.272.5267.1502.View ArticlePubMedGoogle Scholar
- Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, Newman RD: Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007, 7: 93-104. 10.1016/S1473-3099(07)70021-X.View ArticlePubMedGoogle Scholar
- Nosten F, McGready R, Simpson JA, Thwai KL, Balkan S, Cho T, Hkirijaroen L, Looareesuwan S, White NJ: Effects of Plasmodium vivax malaria in pregnancy. Lancet. 1999, 354: 546-549. 10.1016/S0140-6736(98)09247-2.View ArticlePubMedGoogle Scholar
- Singh N, Shukla MM, Sharma VP: Epidemiology of malaria in pregnancy in central India. Bull World Health Organ. 1999, 77: 567-572.PubMed CentralPubMedGoogle Scholar
- Menendez C, D'Alessandro U, ter Kuile FO: Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect Dis. 2007, 7: 126-135. 10.1016/S1473-3099(07)70024-5.View ArticlePubMedGoogle Scholar
- Gamble C, Ekwaru PJ, Garner P, ter Kuile FO: Insecticide-treated nets for the prevention of malaria in pregnancy: a systematic review of randomised controlled trials. PLoS Med. 2007, 4: e107-10.1371/journal.pmed.0040107.PubMed CentralView ArticlePubMedGoogle Scholar
- Crawley J, Hill J, Yartey J, Robalo M, Serufilira A, Ba-Nguz A, Roman E, Palmer A, Asamoa K, Steketee R: From evidence to action? Challenges to policy change and programme delivery for malaria in pregnancy. Lancet Infect Dis. 2007, 7: 145-155. 10.1016/S1473-3099(07)70026-9.View ArticlePubMedGoogle Scholar
- Hill J, Kazembe P: Reaching the Abuja target for intermittent preventive treatment of malaria in pregnancy in African women: a review of progress and operational challenges. Trop Med Int Health. 2006, 11: 409-418. 10.1111/j.1365-3156.2006.01585.x.View ArticlePubMedGoogle Scholar
- ter Kuile FO, van Eijk AM, Filler SJ: Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA. 2007, 297: 2603-2616. 10.1001/jama.297.23.2603.View ArticlePubMedGoogle Scholar
- WHO: Malaria in pregnancy: Guidelines for measuring key monitoring and evaluation indicators. 2007, Geneva, World Health OrganizationGoogle Scholar
- White NJ: How antimalarial drug resistance affects post-treatment prophylaxis. Malar J. 2008, 7: 9-10.1186/1475-2875-7-9.PubMed CentralView ArticlePubMedGoogle Scholar
- Green MD, van Eijk AM, Kuile van Ter FO, Ayisi JG, Parise ME, Kager PA, Nahlen BL, Steketee R, Nettey H: Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. J Inf Dis. 2007, 196: 1403-1408. 10.1086/522632.View ArticleGoogle Scholar
- WHO: Susceptibility of Plasmodium falciparum to antimalarial drugs. Report on Global Monitoring 1996–2004. 2005, Geneva: World Health OrganizationGoogle Scholar
- Brabin BJ, Romagosa C, Abdelgalil S, Menendez C, Verhoeff FH, McGready R, Fletcher KA, Owens S, D'Alessandro U, Nosten F, Fischer PR, Ordi J: The sick placenta-the role of malaria. Placenta. 2004, 25: 359-378. 10.1016/j.placenta.2003.10.019.View ArticlePubMedGoogle Scholar
- Parise ME, Lewis LS, Ayisi JG, Nahlen BL, Slutsker L, Muga R, Sharif SK, Hill J, Steketee RW: A rapid assessment approach for public health decision-making related to the prevention of malaria during pregnancy. Bull World Health Organ. 2003, 81: 316-323.PubMed CentralPubMedGoogle Scholar
- Menendez C, Bardaji A, Sigauque B, Romagosa C, Sanz S, Serra-Casas E, Macete E, Berenguera A, David C, Dobano C, Naniche D, Mayor A, Ordi J, Mandomando I, Aponte JJ, mabunda S, Alonso PL: A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. PLoS ONE. 2008, 3: e1934-10.1371/journal.pone.0001934.PubMed CentralView ArticlePubMedGoogle Scholar
- Sirima SB, Cotte AH, Konate A, Moran AC, Asamoa K, Bougouma EC, Diarra A, Ouedraogo A, Parise ME, Newman RD: Malaria prevention during pregnancy: assessing the disease burden one year after implementing a program of intermittent preventive treatment in Koupela District, Burkina Faso. Am J Trop Med Hyg. 2006, 75: 205-211.PubMedGoogle Scholar
- Verhoeff F, Brabin B, Chimsuku L, Kazembe P, Broadhead R: An analysis of the determinants of anaemia in pregnant women in rural Malawi – A basis for action. Ann Trop Med Parasitol. 1999, 93: 119-133. 10.1080/00034989958609.View ArticlePubMedGoogle Scholar
- Brabin BJ, Agbaje SO, Ahmed Y, Briggs ND: A birthweight nomogram for Africa, as a malaria-control indicator. Ann Trop Med Parasitol. 1999, 93 (Suppl 1): S43-57. 10.1080/00034989957736.PubMedGoogle Scholar
- Uddenfeldt Wort U, Warsame M, Brabin BJ: Potential use of birthweight indicators in rural Tanzania for monitoring malaria control in pregnancy. Public Health. 2008, 122: 923-932. 10.1016/j.puhe.2007.12.012.View ArticlePubMedGoogle Scholar
- Uddenfeldt Wort U, Hastings IM, Carlstedt A, Mutabingwa TK, Brabin BJ: Impact of El Nino and malaria on birthweight in two areas of Tanzania with different malaria transmission patterns. Int J Epidemiology. 2004, 33: 1311-1319. 10.1093/ije/dyh256.View ArticleGoogle Scholar
- Savage EJ, Msyamboza K, Gies S, D'Alessandro U, Brabin BJ: Maternal anaemia as an indicator for monitoring malaria control in pregnancy in sub-Saharan Africa. BJOG. 2007, 114: 1222-1231. 10.1111/j.1471-0528.2007.01420.x.View ArticlePubMedGoogle Scholar
- Broek Van den N, Rogerson S, Mhango C, Kambala B, White S, Molyneux M: Anaemia in pregnancy in Southern Malawi: prevalence and risk factors. Br J Obstet Gynaecol. 2000, 107: 445-451.View ArticleGoogle Scholar
- Msyamboza K, Senga E, Tetteh-Ashong E, Kazembe P, Brabin BJ: Estimation of effectiveness of interventions for malaria control in pregnancy using the screening method. Int J Epidemiology. 2007, 36: 406-411. 10.1093/ije/dyl301.View ArticleGoogle Scholar
- Menendez C, Romagosa C, Ismail MR, Carrilho C, Saute F, Osman N, Machungo F, Bardaji A, Quinto L, Mayor A: An autopsy study of maternal mortality in Mozambique: the contribution of infectious diseases. PLoS Med. 2008, 5: e44-10.1371/journal.pmed.0050044.PubMed CentralView ArticlePubMedGoogle Scholar
- Brabin BJ, Hakimi M, Pelletier D: An analysis of anemia and pregnancy-related maternal mortality. J Nutrition. 2001, 131: 604S-614S. discussion 614S–615SGoogle Scholar
- Brabin L, Verhoeff FH, Kazembe P, Brabin BJ, Chimsuku L, Broadhead R: Improving antenatal care for pregnant adolescents in southern Malawi. Acta Obstet Gynecol Scand. 1998, 77: 402-409. 10.1034/j.1600-0412.1998.770408.x.View ArticlePubMedGoogle Scholar
- Uddenfeldt Wort U, Warsame M, Brabin BJ: Birth outcomes in adolescent pregnancy in an area with intense malaria transmission in Tanzania. Acta Obstet Gynecol Scand. 2006, 85: 949-954.View ArticleGoogle Scholar
- van Eijk AM, Ayisi JG, ter Kuile FO, Slutsker L, Otieno JA, Misore AO, Odondi JO, Rosen DH, Kager PA, Steketee RW: Implementation of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in Kisumu, western Kenya. Trop Med Int Health. 2004, 9: 630-637. 10.1111/j.1365-3156.2004.01242.x.View ArticlePubMedGoogle Scholar
- Gies S, Coulibaly S, Outtana F, Clotilde K, Brabin B, d'Allesandro U: A community effectiveness trial of strategies promoting intermittent preventive treatment with sulfadoxine-pyrimethamine compared to weekly chloroquine in pregnant women in rural Burkina Faso. Malar J. 2008, 7: 180-10.1186/1475-2875-7-180.PubMed CentralView ArticlePubMedGoogle Scholar
- WHO: The safety of medicines in public health programmes: pharmacovigilance an essential tool. 2006, Geneva: WHOGoogle Scholar
- Pirmohamed M, Atuah KN, Dodoo AN, Winstanley P: Pharmacovigilance in developing countries. BMJ. 2007, 335: 462-10.1136/bmj.39323.586123.BE.PubMed CentralView ArticlePubMedGoogle Scholar
- Talisuna AO, Staedke SG, D'Alessandro U: Pharmacovigilance of antimalarial treatment in Africa: is it possible?. Malar J. 2006, 5: 50-10.1186/1475-2875-5-50.PubMed CentralView ArticlePubMedGoogle Scholar
- Kennedy DL, Uhl K, Kweder SL: Pregnancy exposure registries. Drug Saf. 2004, 27: 215-228. 10.2165/00002018-200427040-00001.View ArticlePubMedGoogle Scholar
- Dellicour S, Hall S, Chandramohan D, Greenwood B: The safety of artemisinins during pregnancy: a pressing question. Malar J. 2007, 6: 15-10.1186/1475-2875-6-15.PubMed CentralView ArticlePubMedGoogle Scholar
- WHO: The Importance of Pharmacovigilance – Safety Monitoring of Medicinal Products. Chapter 6 – Pharmacovigilance in International Health. 2002, Geneva: WHOGoogle Scholar
- Greenwood B, Alonso P, ter Kuile F, Hill J, Steketee R: Malaria in pregnancy: priorities for research. Lancet Infect Dis. 2007, 7: 169-174. 10.1016/S1473-3099(07)70028-2.View ArticlePubMedGoogle Scholar
- Stokes E, Dumbayo I, Owens S, Brabin L: The right to remain silent: aqualitative study of the medical and social ramifications of pregnancy disclosure for Gambia women. Br J Obstet Gynaecol. 2008,Google Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.